OBJECTIVE: HER2 negative carcinomas of the breast pose a challenge for treatment due to redundancies in potential drug targets and poor patient outcomes. Our aim was to investigate the role of L-type amino acid transporter - LAT1 as a potential prognosticator and a drug target. METHODS: In this retrospective work, we have studied the expression of LAT1 in 145 breast cancer tissues via immunohistochemistry. Overall survival analysis was used to evaluate patient outcome in various groups of our cohort. RESULTS: Positive LAT1 expression was found in 27 (84.4%) luminal A subtype, 27 (64.3%) luminal B/triple positive subtype, 29 (82.9%) triple negative subtype, and 24 (66.7%) HER2-only positive subtype (p=0.1). Interestingly, negative correlation was found between LAT1 and HER2; where positive expression of LAT1 was found in 56 (83.6%) cases in negative HER2 group and 51 (65.4%) cases from positive HER2 group (p=0.01). Unfortunately, we were unable to report significant survival differences when LAT1 expression was studied in the negative HER2 group. Nevertheless, five incidents of mortality (out of 55) were reported in LAT1+/HER2- group compared to none in the LAT1-/HER2- group (N=11). CONCLUSION: Our findings of overexpression of LAT1 in negative HER2 group suggest a role of this protein as prognosticator and drug target in a challenging therapeutic cohort.
.

Central European Institute of Technology Brno University of Technology Purkynova Brno Czech Republic

Department of Applied Biology Jordan University of Science and Technology Irbid Jordan

Department of Chemistry and Biochemistry Mendel University in Brno Zemedelska 1 Brno Czech Republic

Department of Medical Laboratory Sciences Jordan University of Science and Technology Irbid Jordan

Department of Pathology Jordan University of Science and Technology Irbid Jordan

Zobrazit více v PubMed

Bodoor K, Abu-Sheikha A, Matalka I, et al. Immunohistochemical analysis of heat shock proteins in triple negative breast cancer: HSP60 expression is a marker of poor prognosis. Eur J Gynaecol Oncol. 2018;39:926–34.

Cha YJ, Kim ES, Koo JS. Amino acid transporters and glutamine metabolism in breast cancer. Int J Mol Sci. 2018;19:907. PubMed PMC

Dickens D, Chiduza GN, Wright GS, et al. Modulation of LAT1 (SLC7A5) transporter activity and stability by membrane cholesterol. Sci Rep. 2017;7:43580. PubMed PMC

El-Ansari R, Craze ML, Alfarsi L, et al. The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer. Breast Cancer Res Treat. 2019;175:27–38. PubMed

El Ansari R, Craze ML, Diez-Rodriguez M, et al. The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes. Br J Cancer. 2018a;118:1115–22. PubMed PMC

El Ansari R, Craze ML, Miligy I, et al. The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours. Breast Cancer Res. 2018b;20:21. PubMed PMC

El Ansari R, McIntyre A, Craze ML, et al. Altered glutamine metabolism in breast cancer; subtype dependencies and alternative adaptations. Histopathology. 2018c;72:183–90. PubMed

Fotiadis D, Kanai Y, Palacín M. The SLC3 and SLC7 families of amino acid transporters. Mol Aspects Med. 2013;34:139–58. PubMed

Furuya M, Horiguchi J, Nakajima H, et al. Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer Sci. 2012;103:382–9. PubMed

Haddad Y, Heger Z, Adam V. Targeting neuroblastoma cell surface proteins: recommendations for homology modeling of hNET, ALK, and TrkB. Front Mol Neurosci. 2017;10 PubMed PMC

Hafliger P, Charles RP. The L-Type amino acid transporter LAT1-an emerging target in cancer. Int J Mol Sci. 2019;20:2428. PubMed PMC

Liang Z, Cho HT, Williams L, et al. Potential biomarker of L-type amino acid transporter 1 in breast cancer progression. Nucl Med Mol Imaging. 2011;45:93–102. PubMed PMC

Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–70. PubMed

Napolitano L, Scalise M, Koyioni M, et al. Potent inhibitors of human LAT1 (SLC7A5) transporter based on dithiazole and dithiazine compounds for development of anticancer drugs. Biochem Pharmacol. 2017;143:39–52. PubMed

Ring BZ, Seitz RS, Beck R, et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3039–47. PubMed

Scalise M, Galluccio M, Console L, et al. The human SLC7A5 (LAT1): The intriguing histidine/large neutral amino acid transporter and its relevance to human health. Front Chem. 2018;6:243. PubMed PMC

Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12:278–87. PubMed

Sevigny CM, Sengupta S, Luo Z, et al. SLCs contribute to endocrine resistance in breast cancer: role of SLC7A5 (LAT1) BioRxiv. 2019:555342.

Singh N, Scalise M, Galluccio M, et al. Discovery of potent inhibitors for the large neutral amino acid transporter 1 (LAT1) by structure-based methods. Int J Mol Sci. 2018;20:27. PubMed PMC

Yan R, Zhao X, Lei J, et al. Structure of the human LAT1–4F2hc heteromeric amino acid transporter complex. Nature. 2019;568:127–30. PubMed